ACTU: Actuate Therapeutics Inc. Company Value to Net Income

Actuate Therapeutics Inc. - graphic logo of issuer ACTU

The market trend for Actuate Therapeutics, Inc. (ACTU) shares on the GURU.Markets platform, where the indicator stands at -0.40, is driven by the success of complex tumor therapies and the pace of subject group formation. Current quotes price in R&D costs and the anticipation of Phase II trial results. In the long term, the business is based on the global promotion of elraglusib to capture market share within the oncology sector.

Price to Earnings Ratio: Actuate Therapeutics, Inc. (ACTU) for 03/21/2025 - 11/17/2026

Comprehensive metric breakdowns and analytics for Actuate Therapeutics Inc. (ACTU)

Summary company analysis:ACTU, Actuate Therapeutics
Flagship merchandise of Actuate Therapeutics

The P/E ratio reflects the market value of a business relative to its generated net income. Analyzing the annual P/E of a company allows an investor to quickly diagnose asset overvaluation and debt service risks. The trend of this ratio on the chart serves as an indicator of the balance between the cost of capital and growth rates. For Actuate Therapeutics, Inc. (ACTU), a high valuation is often justified by its scientific mission and the value of option packages used to retain leading oncologists.

Key competitors

ONC: Company Value to Net Income|Price to Earnings Ratio HALO (Halozyme Inc.)|RVMD (RevMed) - Company Value to Net Income|P/E Multiple AAPG (ascentage.com)|CGON - Price to Earnings Ratio|URGN: Price to Earnings Ratio|BCAX - P/E Multiple|Personalis Corp (PSNL) - Price to Earnings Ratio|Erasca Corp - Company Value to Net Income|DCTH (Delcath Systems Inc) - P/E Multiple|Market Cap to Earnings Y-mAbs Therapeutics, Inc. YMAB|P/E Multiple AURA|Price to Earnings Ratio Candel Therapeutics, Inc. CADL|P/E Multiple ARAY (Accuray, Inc.)|SELLAS Life Sciences - Price to Earnings Ratio|CTOR: Price to Earnings Ratio|Company Value to Net Income HURA (TuHURA Biosciences Inc.)|TARA (Protara Therapeutics) - Price to Earnings Ratio|Market Cap to Earnings Fate Therapeutics Corp (FATE)|Price to Earnings Ratio WHWK|Price to Earnings Multiple TCRX (TScan Therapeutics, Inc.)|P/E Multiple CSBR|XBIT - Market Cap to Earnings|CEL-SCI Corporation - Price to Earnings Ratio|Company Value to Net Income OSTX|radiopharmtheranostics.com - P/E Multiple|ARTV: Price to Earnings Ratio|ANL (adlainortye.com) - Price to Earnings Ratio|VERU - Business Payback Period|TPST (Tempest Therapeutics, Inc.) - P/E Multiple|P/E Multiple xiliotx.com|Price to Earnings Ratio Enochian BioSciences (RENB)|Price to Earnings Ratio MURA (Mural Oncology PLC)|Price to Earnings Ratio Kairos Pharma Ltd KAPA|P/E Multiple OnKure Therapeutics Inc OKUR|CytoMed Therapeutics - P/E Multiple|Business Payback Period Curis CRIS|APLM: P/E Multiple|Price to Earnings Ratio Tharimmune, Inc.|ADVB (Advanced Biomed) - P/E Multiple|Genprex - Market Cap to Net Income|Price to Earnings Ratio calidibio.com (CLDI)|SBFM (Sunshine Biopharma Inc.) - Company Value to Net Income|P/E Multiple XBIO (Xenetic Biosciences)|Salarius Pharmaceuticals (SLRX) - Market Cap to Earnings|PPBT: Price to Earnings Ratio|Company Value to Net Income AONC (American Oncology Network, Inc.)|BeOne Medicines (BGNE) - Price to Earnings Ratio|Checkpoint Therapeutics, Inc (CKPT) - P/E Multiple|Price to Earnings Ratio Elevation Oncology, Inc.|ICAD: Company Value to Net Income|Price to Earnings Ratio ikenaoncology.com (IKNA)|Price to Earnings Ratio NTBL (Notable Labs, Ltd.)|P/E Multiple VIRX (viracta.com)|MOR - Price to Earnings Ratio|NAYA - Price to Earnings Ratio|Market Cap to Net Income AAPGV